基于BCL2i的疗法和慢性淋巴细胞白血病中新出现的耐药性
Wing Fai Li1, Eleftheria Atalla2, Jiaxin Dong3
1Department of Internal Medicine, Jacobi Medical Center, Bronx, NY 10461, USA.
Cells
|November 27, 2024
概括
作为BCL-2抑制剂的Venetoclax在慢性淋巴细胞白血病 (CLL) 中表现有前途. 组合疗法改善了结果,克服了耐药性,为CLL患者提供了新的希望.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 分子生物学分子生物学
背景情况:
- 过度表达的BCL-2蛋白驱动慢性淋巴细胞白血病 (CLL) 病原体和不良预后.
- 威尼托克拉克斯 (BCL-2 抑制剂) 在CLL治疗中表现出有效性,但耐药性仍然是一个挑战.
研究的目的:
- 审查BCL-2家族蛋白质在CLL亡中的作用.
- 讨论CLL中的venetoclax耐药机制.
- 为突出基于venetoclax的CLL组合疗法的进展.
主要方法:
- 在CLL中使用BCL-2抑制剂的文献综述.
- 对venetoclax组合的临床试验数据的分析.
- 探索CLL对BCL2i的抵抗机制.
主要成果:
- 与BTK抑制剂或CD20抗体的Venetoclax组合优于化疗免疫疗法.
- 实现了不可检测的最小残留疾病 (uMRD) 和持久的缓解.
- 确定了包括BCL-2突变和途径改变在内的耐药性机制.
结论:
- 基于Venetoclax的组合可以改善CLL的无进展生存率.
- 针对多个途径是克服venetoclax耐药性的关键.
- 不断发展的治疗策略正在改变CLL的管理.
更多相关视频
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
